Modelling genetic and clinical heterogeneity in epithelial ovarian cancers

Carcinogenesis

Volumn 32, Issue 10, 2011, Pages 1540-1549

  Lawrenson, Kate ^c   Sproul, Duncan ^b   Grun, Barbara ^a   Notaridou, Maria ^a   Benjamin, Elizabeth ^a   Jacobs, Ian J ^a   Dafou, Dimitra ^a   Sims, Andrew H ^b   Gayther, Simon A ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CONNECTIVE TISSUE GROWTH FACTOR; K RAS PROTEIN; RGS4 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; THROMBOSPONDIN 1;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRUCTURE; CELL TRANSFORMATION; CLINICAL FEATURE; CMCY GENE; CONTROLLED STUDY; CORRELATION COEFFICIENT; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; GENETIC MODEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR GENETICS; NEPHROBLASTOMA; ONCOGENE; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING; TUMOR GENE;

ADULT; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PRIMARY CELL CULTURE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 80053155727     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr140     Document Type: Article

References (53)

1. Köbel,M. et al. (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med., 5, e232.
2. Singer,G. et al. (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol., 29, 218-224.
3. Willner,J. et al. (2007) Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum. Pathol., 38, 607-613.
4. Ahmed,A.A. et al. (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol., 221, 49-56.
5. Sieben,N.L. et al. (2004) In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J. Pathol., 202, 336-340.
6. Obata,K. et al. (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res., 58, 2095-2097.
7. Gemignani,M.L. et al. (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol. Oncol., 90, 378-381.
8. Wisman,G.B. et al. (2003) Telomerase in relation to expression of p53, c-Myc and estrogen receptor in ovarian tumours. Int. J. Oncol., 23, 1451-1459.
9. Chen,C.H. et al. (2005) Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer. Int. J. Gynecol. Cancer, 15, 878-883.
10. Kusakari,T. et al. (2003) C-erbB-2 or mutant Ha-ras induced malignant transformation of immortalized human ovarian surface epithelial cells in vitro. Br. J. Cancer, 89, 2293-2298.
11. Liu,J. et al. (2004) A genetically defined model for human ovarian cancer. Cancer Res., 64, 1655-1663.
12. Sasaki,R. et al. (2009) Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis, 30, 423-431.
13. Tothill,R.W. et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res., 14, 5198-5208.
14. Jazaeri,A.A. et al. (2002) Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl Cancer Inst., 94, 990-1000.
15. Jazaeri,A.A. et al. (2003) Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol. Carcinog., 36, 53-59.
16. Jazaeri,A.A. et al. (2005) Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin. Cancer Res., 11, 6300-6310.
17. Anglesio,M.S. et al. (2008) Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol. Cancer Res., 6, 1678-1690.
18. Berchuck,A. et al. (2009) Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin. Cancer Res., 15, 2448-2455.
19. Marchini,S. et al. (2008) Analysis of gene expression in early-stage ovarian cancer. Clin. Cancer Res., 14, 7850-7860.
20. Lee,E.Y. et al. (1984) Modulation of secreted proteins of mouse mammary epithelial cells by the collagenous substrata. J. Cell Biol., 98, 146-155.
21. Debnath,J. et al. (2005) Modelling glandular epithelial cancers in threedimensional cultures. Nat. Rev. Cancer, 5, 675-688.
22. Petersen,O.W. et al. (1992) Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc. Natl Acad. Sci. USA, 89, 9064-9068.
23. Lawrenson,K. et al. (2010) Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a threedimensional model of early stage ovarian cancer. Neoplasia, 12, 317-325.
24. Li,N.F. et al. (2004) A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. Lab. Invest., 84, 923-931.
25. Du,P. et al. (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics, 24, 1547-1548.
26. Smyth,G.K. (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol., 3, No. 1, Article 3.
27. Yoshihara,K. et al. (2009) Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci., 100, 1421-1428.
28. Dai,M. et al. (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res., 33, 175, version 12.
29. Lawrenson,K. et al. (2009) In vitro three-dimensional modelling of human ovarian surface epithelial cells. Cell Prolif., 42, 385-393.
30. Auersperg,N. et al. (1984) Human ovarian surface epithelium in primary culture. In Vitro, 20, 743-755.
31. Musgrove,E.A. et al. (2009) Identification of functional networks of estrogen-and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One, 3, e2987.
32. Bild,A.H. et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature, 439, 353-357.
33. Macgregor,J.E. et al. (1971) Improved prognosis of cervical cancer due to comprehensive screening. Lancet, 1, 74-76.
34. Collin,S.M. et al. (2008) Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol., 9, 445-452.
35. Tabar,L. et al. (2003) Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet, 361, 1405-1410.
36. Köbel,M. et al. (2010) Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol. Oncol., 116, 50-56.
37. Vogelstein,B. et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med., 319, 525-532.
38. Shimizu,M. et al. (2000) Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int. J. Gynecol. Pathol., 19, 158-163.
39. Mayr,D. et al. (2006) KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol. Oncol., 103, 883-887.
40. Grun,B. et al. (2009) Three-dimensional in vitro cell biology models of ovarian and endometrial cancer. Cell Prolif., 42, 219-228.
41. Kobayashi,C. et al. (2005) Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Cancer, 103, 174-180.
42. Watson,N. et al. (1996) RGS family members: GTPase-activating proteins for heterotrimeric G-protein alpha-subunits. Nature, 383, 172-175.
43. Hurst,J.H. et al. (2009) Regulator of G-protein signalling expression and function in ovarian cancer cell lines. Cell. Mol. Biol. Lett., 14, 153-174.
44. Niedergethmann,M. et al. (2007) Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic scid mouse model. Br. J. Cancer, 97, 1432-1440.
45. Xie,Y. et al. (2009) Breast cancer migration and invasion depend on proteasome degradation of regulator of g-protein signaling 4. Cancer Res., 69, 5743-5751.
46. Barbolina,M.V. et al. (2009) Downregulation of connective tissue growth factor by three-dimensional matrix enhances ovarian carcinoma cell invasion. Int. J. Cancer, 125, 816-825.
47. Ijichi,H. et al. (2006) Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev., 20, 3147-3160.
48. Greenaway,J. et al. (2009) Abt-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol. Cancer Ther., 8, 64-74.
49. Laklai,H. et al. (2009) Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proc. Natl Acad. Sci. USA, 106, 17769-17774.
50. Zubac,D.P. et al. (2009) The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J. Urol., 182, 2144-2149.
51. Alvarez,A.A. et al. (2001) Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Gynecol. Oncol., 82, 273-278.
52. Goode,F.L. et al. (2010) Identification and functional analysis of four novel ovarian cancer susceptibility loci identified in a genome-wide association study. Nat. Genet., 42, 874-879.
53. Kurman,R.J. et al. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol., 34, 433-443.